Patent US9456995B2 successfully refreshed from Google Patents.
US9456995B2
Active / In Force
US
⏱️ 6.7 years remaining
Methods for inhibition of BNIP3 and prevention and treatment of ischemia reperfusion injury by tetra-O-methyl nordihydroguaiaretic acid
Assignee: Johns Hopkins University
•
Filing: 2013-07-18
•
Granted: 2016-10-04
•
Expires: 2033-07-18
Abstract
Abstract Provided herein are methods for prevention and treatment of ischemia-reperfusion (IR) injury in the cardiac myocytes of a subject, by administration to the subject, a compound of formula I, or a salt, solvate, or stereoisomer thereof, in a sufficient amount either prior to, or during and/or after an ischemic event to mitigate or prevent IR injury to the cardiac tissue. Pharmaceutical compositions including the compound of formula I, or a salt, solvate, or stereoisomer thereof, and/or at least one additional therapeutic agent, are also provided.
Inventors
- 👤 Ru Chih Huang
- 👤 Kotohiko Kimura
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 22:59
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/075; A61K31/085; A61K31/09; A61P; A61P43/00; A61P9/00; A61P9/10
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
49 words
A method for the treatment of Ischemia/Reperfusion (IR) injury in the cardiac myocytes of a subject comprising administering to the subject during and/or after the ischemic event, the compound of formula (I), or a solvate, or stereoisomer thereof, in a sufficient amount to decrease the amount of IR injury.
Claim 2
Independent Claim
49 words
A method for the treatment of Ischemia/Reperfusion (IR) injury in the cardiac myocytes of a subject comprising administering to the subject during and/or after the ischemic event, the compound of formula (I), or a solvate, or stereoisomer thereof, in a sufficient amount to decrease the amount of IR injury.
Claim 3
Dependent Claim
29 words
The method of claim 1 , wherein the amount administered to the subject is sufficient to provide a concentration in the blood of between 1 μM to 50 μM.
Claim 4
Dependent Claim
34 words
The method of claim 1 , wherein the compound of formula (I), or a solvate, or stereoisomer thereof, is administered to the subject after reperfusion is initiated to the cardiac myocytes of the subject.
Claim 5
Dependent Claim
21 words
The method of claim 1 , wherein the compound is administered to the subject with at least one additional therapeutic agent.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2019-10-04 | 2020-04-04 | 2020-10-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2023-10-04 | 2024-04-04 | 2024-10-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2027-10-04 | 2028-04-04 | 2028-10-04 | $7700.00 | Pending Window |